EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Real-World Use of Baricitinib for Severe Alopecia Areata in Spain: The ROSE-S Observational Study

Sergio Vano-Galvan, David Saceda-Corralo, Salvador Arias-Santiago, Román Barabash-Neila, Yolanda Gilaberte, Virginia Velasco-Tamariz, Iñigo Martínez de Espronceda, Ignasi Figueras-Nart, Carlos Abril, Andrea Combalia, Sergio Santos-Alarcon, Alberto Romero-Maté und 8 weitere

Clinical, Cosmetic and Investigational Dermatology · 2026-11 · Volume 19 · 1-18

DOI: 10.2147/ccid.s616948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-11. Verfasst von Sergio Vano-Galvan und 19 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss. Baricitinib is the first oral Janus kinase inhibitor approved for severe AA in adults. This study aimed to describe persistence, treatment patterns, effectiveness and patient satisfaction in adults receiving baricitinib in routine clinical practice in Spain.

Methods

A multicenter, retrospective observational cohort study with a cross-sectional PRO assessment was performed in adults with severe AA (SALT score ≥ 50) treated with baricitinib at 15 Spanish hospitals from June 2022 and with at least 36 weeks of follow-up, regardless of whether they remained on treatment. Sociodemographic, clinical, and treatment data were collected. Effectiveness was assessed using SALT score at treatment initiation and at 12, 24, 36, and 52 weeks, and the percentage of patients with SALT≤ 20. A cross-sectional visit (≥ 36 weeks since baricitinib initiation) collected the Treatment Satisfaction Questionnaire for Medication (TSQM), four ad-hoc questions regarding treatment satisfaction in specific areas (body hair, nails, beard, eyebrows/eyelashes), and the Scalp Hair Assessment PRO™. Analyses, all descriptive, summarized outcomes overall and by affected area, with persistence assessed via Kaplan-Meier.

Results

109 patients (67.9% females) were included in the study, with a mean (standard deviation [SD]) AA duration of 11.1 (11.0) years. The mean (SD) baseline SALT score was 81.1 (18.7) and 75.0% started with baricitinib monotherapy. At week 52, 91.8% continued treatment and 71.1% achieved a SALT≤ 20. Mean (SD) treatment satisfaction was 341.0 (51.4) out of 400 points on the TSQM. In subpopulations affected in specific areas, persistence rates exceeded 87%, at least 55% achieved SALT≤ 20 at week 52, and mean satisfaction score was above 320.

Conclusion

In this real-world cohort in Spain, baricitinib use was associated with high treatment persistence and satisfaction, together with improved SALT scores in adults with severe AA, including those with involvement of body hair, nails, beard, and eyebrows/eyelashes. Plain Language Summary: Alopecia areata (AA) is a common autoimmune disease. It makes hair fall out in patches, without leaving scars. It affects men and women of all ages and often causes emotional distress and a lower quality of life. We studied 109 adults with severe AA who were treated with baricitinib, a tablet approved for this condition, at 15 hospitals in Spain. For every patient, at least 36 weeks had passed since starting baricitinib, whether or not they were still taking it when we collected the data. We measured how many patients stayed on treatment, how their hair regrew, and how satisfied they felt, at several points up to 52 weeks. By week 52, most patients were still taking baricitinib, and their scalp hair loss had improved significantly. Patients felt satisfied with the treatment, and almost 80% said their hair loss had improved. Even so, in everyday clinical practice, baricitinib use was associated with high treatment persistence, patient-reported satisfaction, and improvement in patients’ scalp hair loss scores and perception in adults with severe AA, including those with involvement of body hair, nails, beard, and eyebrows/eyelashes. These findings could help guide clinical decisions and improve the management of severe AA. Infographic summarizing population, methodology and findings for baricitinib in severe alopecia areata. Population: Adults with severe alopecia areata (AA) with SALT greater than or equal to 50, treated with baricitinib since June 2022 and with at least 36 weeks of follow-up. Methodology: Multicenter, retrospective observational cohort study with a cross-sectional PRO assessment conducted in 15 Spanish hospitals. A timeline shows a patient recruitment period from October 2024 to February 2025. The index date corresponded to baricitinib initiation. Retrospective data collection included AA diagnosis, previous AA treatments and clinical characteristics. Follow-up assessments, when available, were conducted at Weeks 12, 24, 36, and 52 and included sociodemographic and clinical characteristics, SALT, and AA treatment patterns. At the end of follow-up (greater than or equal to 36 weeks after baricitinib initiation), a cross-sectional assessment visit includes SALT and AA treatment patterns, together with patient-reported outcomes: TSQM, ad hoc treatment satisfaction in specific areas, and patient-reported scalp hair assessment.

Findings

In Spanish routine clinical practice, baricitinib showed high treatment persistence (91.8 percent persistence at Week 52), effectiveness (71.1 percent achieved SALT less than or equal to 20 at Week 52), and high patient-reported satisfaction (341 out of 400 points on the TSQM) together with improved perceived scalp hair loss (78.5 percent reported improvement). These results were also observed in patients with involvement of special areas, including body hair, nails, beard hair, and eyebrows or eyelashes.Infographic on baricitinib for severe alopecia areata: population, methodology and findings. Keywords: alopecia areata, baricitinib, real-world study, persistence, effectiveness, patient satisfaction

Zitieren

APA

Vano-Galvan, S., Saceda-Corralo, D., Arias-Santiago, S., Barabash-Neila, R., Gilaberte, Y., Velasco-Tamariz, V., Espronceda, I. M. D., Figueras-Nart, I., Abril, C., Combalia, A., Santos-Alarcon, S., Romero-Maté, A., Blanco, C. C., López-Bran, E., Ramos-Rodríguez, D., Moro, R., Díaz-Cerezo, S., Moyano, S., Cruz, E. D. L., & Núñez, M. (2026). Real-World Use of Baricitinib for Severe Alopecia Areata in Spain: The ROSE-S Observational Study. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-18. https://doi.org/10.2147/ccid.s616948

Vancouver

Vano-Galvan S, Saceda-Corralo D, Arias-Santiago S, Barabash-Neila R, Gilaberte Y, Velasco-Tamariz V, et al. Real-World Use of Baricitinib for Severe Alopecia Areata in Spain: The ROSE-S Observational Study. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-18. doi:10.2147/ccid.s616948

BibTeX
@article{VanoGalvan2026,
  author = {Vano-Galvan, Sergio and Saceda-Corralo, David and Arias-Santiago, Salvador and Barabash-Neila, Román and Gilaberte, Yolanda and Velasco-Tamariz, Virginia and Espronceda, Iñigo Martínez de and Figueras-Nart, Ignasi and Abril, Carlos and Combalia, Andrea and Santos-Alarcon, Sergio and Romero-Maté, Alberto and Blanco, Cristina Ciudad and López-Bran, Eduardo and Ramos-Rodríguez, Daniel and Moro, Rosa and Díaz-Cerezo, Silvia and Moyano, Sebastián and Cruz, Ester De la and Núñez, Mercedes},
  title = {Real-World Use of Baricitinib for Severe Alopecia Areata in Spain: The ROSE-S Observational Study},
  journal = {Clinical, Cosmetic and Investigational Dermatology},
  year = {2026},
  volume = {Volume 19},
  pages = {1--18},
  doi = {10.2147/ccid.s616948}
}
Kostenlos starten →